Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetically Engineered Mouse Model Mimics Rare Human Bone Disorder

By LabMedica International staff writers
Posted on 25 Jan 2016
A model for the study of the rare bone disorder Hajdu-Cheney syndrome was developed by genetically engineering a line of mice to express a specific Notch2 mutation.

Notch2 is a member of the notch family of transmembrane proteins that share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple, different domain types. More...
Notch family members play a role in a variety of developmental processes by controlling cell fate decisions. The Notch signaling network is an evolutionarily conserved intercellular signaling pathway that regulates interactions between physically adjacent cells. Mutations within the last coding exon of NOTCH2 have been shown to be the main cause of the Hajdu-Cheney syndrome.

Hajdu-Cheney syndrome—an exceedingly rare disease, with fewer than 100 cases ever described—is characterized by osteoporosis and fractures. Development of this disease is associated with NOTCH2 (neurogenic locus notch homolog protein 2) mutations that result in a truncated stable protein that avoids deactivation by the cell.

To study the relationship between the NOTCH2 mutation and the disease syndrome, investigators at the University of Connecticut (Storrs, USA) created a mouse model that reproduced Hajdu-Cheney syndrome by introducing a mutation in the NOTCH2 locus leading to a change at the amino acid level.

They reported in the December 1, 2015, online edition of the Journal of Biological Chemistry that heterozygous mutants were smaller and had shorter femurs than controls; and at one month of age exhibited cancellous and cortical bone osteopenia (lower than normal bone mineral density). As the mice matured, cancellous bone volume was restored partially in male but not female mice, whereas cortical osteopenia persisted in both sexes. Cancellous bone was found to have an increased number of osteoclasts (bone cells that break down bone tissue) and bone resorption, without a decrease in osteoblast (bone precursor cells) number or bone formation.

"Until now, nobody understood why people afflicted with the disease had osteoporosis and fractures," said first author Dr. Ernesto Canalis, professor of orthopedic surgery at the University of Connecticut. "There are a few symptoms of the disease in humans—such as shortened fingers and oddly shaped skull bones—that the mice do not display. But overall, the mouse model is a very good model of the human disease."

Related Links:
University of Connecticut



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.